Itacitinib Adipate
Phase 2Small molecule
Itacitinib Adipate is one of 81 small molecule programs targeting Bronchiolitis Obliterans. It is currently in Phase 2.
2
Indications
2
Total Trials
1
Active Trials
80
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
364 competitors in Myelodysplastic Syndrome
#DrugCompanyPhaseTrials
1Cytosar
TevaPhase 3
Venclexta
AbbViePhase 3
Fludara
SanofiPhase 3
Vidaza
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Idamycin
PfizerPhase 3
Trexall
Alnylam PharmaceuticalsPhase 3
Revlimid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Cellcept
RochePhase 3
Aranesp
AmgenPhase 3
Novantrone
PfizerPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Myelodysplastic Syndrome1 trial
Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell Transplantation
Active, not recruiting·—·Phase 2·NCT04339101·59 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Itacitinib Adipate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- MM.D. Anderson Cancer Center